|
|
Volumn 295, Issue 4, 2006, Pages 369-370
|
|
Looking beyond imatinib: Next line of targeted drugs for CML shows promise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BCR ABL PROTEIN;
BILIRUBIN;
DASATINIB;
IMATINIB;
LIVER ENZYME;
NILOTINIB;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD;
CHROMOSOME 22;
CHROMOSOME 9;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CONSTIPATION;
DIARRHEA;
DRUG DESIGN;
FLUID RETENTION;
GENETIC DISORDER;
HUMAN;
NAUSEA;
PRIORITY JOURNAL;
RASH;
SHORT SURVEY;
SIDE EFFECT;
STEM CELL TRANSPLANTATION;
VOMITING;
|
|
EID: 31344441164
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.295.4.369 Document Type: Short Survey |
|
Times cited : (10)
|
|
References (0)
|